mRNA Beyond COVID: The 2026 Oncology Supply Chain Playbook
When mRNA vaccines rolled out during the pandemic, the world saw the speed of this platform for the first time. What was once considered experimental became a household name.
But inside the biopharma boardrooms, the conversation has shifted. The future of mRNA isn’t about COVID anymore — it’s about oncology. Dozens of clinical trials are testing therapeutic vaccines and personalized cancer treatments. The science is moving faster than ever.
Here’s the catch: the bottleneck is no longer discovery, it’s manufacturing and supply. Experts in the field are clear: unless the industry can secure GMP-grade raw materials, optimize large-scale IVT, and guarantee regulatory documentation, oncology mRNA won’t achieve the same breakthrough speed we saw in 2020.
This playbook summarizes what industry leaders are learning about mRNA in oncology — and how DKSH is helping them prepare.
The Manufacturing Bottlenecks
- IVT bottlenecks: GMP-grade T7 polymerase, capping enzymes, and NTPs are in high demand.
- Scaling challenges: Expanding IVT reactions, purification workflows, and LNP formulation while maintaining yield, consistency, and compliance remains a key constraint.
- Documentation delays: INDs are slowed by gaps in DMF-backed raw materials.
- Cold-chain fragility: Oncology trials require cross-border, temperature-stable logistics.
The Solutions
- GMP Enzymes toolkit: T7 polymerase, RNase inhibitors, pyrophosphatase, vaccinia capping enzymes — backed by 15 FDA-filed DMFs.
- Quality Control for mRNA Substance: qualified ELISA kits, from mRNA Capping Detection to dsRNA Detection or E. Coli detection.
- Regulatory foresight: Compliance with ISO standards, FDA-filled DMF and Halal certification.
Why This Is Urgent
Analysts forecast oncology mRNA will be a multi-billion-dollar market by 2030. The winners won’t just have the best science — they’ll have supply chains that regulators, clinicians, and payers trust.
Conclusion
By 2030, analysts predict oncology mRNA will be a multi-billion-dollar market. The science is already there. The missing link is supply chain resilience — the ability to deliver oncology-grade mRNA inputs consistently, compliantly, and at scale.
Explore our Biopharma product portfolio and discover how DKSH can help you build a compliant, resilient supply chain for your oncology programs.
